• Home Blog Tag Generalised myasthenia gravis

Generalised Myasthenia Gravis

Nov 17, 2026

Johnson & Johnson’s CAPLYTA Achieves Positive Results in Second Pivotal Phase 3 Bipolar Mania Study; US FDA Approves Klygefa for Adults with Generalised Myasthenia Gravis; Roche’s Gazyva/Gazyvaro Secures First FDA Approval for Primary Membranous Nephropathy; Summit Therapeutics Provides Regulatory Update on Ivonescimab BLA; Novo Submits Etavopivat for Regulatory Approval as a Once-Daily Treatment for Sickle Cell Disease

Newsletter/Whitepaper